Semaglutide and tirzepatide have well-established weight-loss and cardiometabolic benefits, but their effects on bone health have been comparatively poorly defined — animal and in vitro studies have suggested a protective effect, while the sparse human data has been harder to interpret. A February 2026 study in the Journal of Clinical Endocrinology & Metabolism is the first matched cohort study directly comparing semaglutide and tirzepatide users to non-users specifically in a population at elevated fracture risk.[1]
Study design
Researchers at Weill Cornell Medical College conducted a single-center retrospective study of 255 adults who had used semaglutide or tirzepatide for at least 6 months and had DXA (bone density) scans both before initiation and at least 6 months after, matched by age, sex, BMI, and diabetes status to 255 non-users with comparable scan histories.[1] The cohort was 92% female, mean age 64±9 years, mean BMI 31.0±5.6. At baseline, 75% of participants already had osteopenia or osteoporosis, and 27% had a prior fragility fracture — reflecting the study's specific focus on a fracture-risk population, not a general GLP-1 user population.
The key finding: effects diverge by diabetes status
Across the full cohort, both the GLP-1 group and the matched control group showed significant declines in total hip and femoral neck bone mineral density, of similar overall magnitude — meaning GLP-1 use was not uniformly associated with greater bone loss than controls across the whole study population.[1] The more specific finding emerged in the subgroup analysis:
- In patients without diabetes: the GLP-1 group showed significantly greater annualized total hip bone loss than matched controls (-1.0% vs. -0.6%, p=0.04)
- In patients with diabetes and class II obesity or greater: total hip BMD change was actually slightly positive in the GLP-1 group versus a decline in controls (+0.1% vs. -1.0%), though this difference did not reach statistical significance (p=0.20)
Across the full cohort, the amount of weight lost directly predicted the magnitude of bone loss at both sites measured: r=0.32 at the total hip and r=0.17 at the femoral neck (both p<0.01).[1]
These findings suggest GLP-1 RA's effects on bone may differ by diabetes status, with weight loss driving bone loss in patients without diabetes.
Why weight loss itself may be the key variable
This pattern is consistent with a broader, longer-standing body of research on weight loss generally — including from bariatric surgery and calorie restriction — showing that substantial weight loss by nearly any method tends to reduce bone density, likely through reduced mechanical loading on the skeleton and hormonal changes accompanying fat loss. The open question this study raises, rather than answers, is whether GLP-1-specific mechanisms add to that baseline weight-loss effect, or whether the effect is fully explained by the amount of weight lost — a distinction the correlation data (r=0.32) is suggestive of, but the matched-control comparison in diabetic patients complicates.
Fracture risk signals from larger trials
Separately from this bone-density-specific cohort study, a large cardiovascular outcomes trial of more than 17,000 participants — widely understood in the field to refer to the SELECT trial of semaglutide — has reported findings of increased hip and pelvic fracture incidence specifically in adults 75 years and older using semaglutide compared to placebo, a signal reported at nearly five times higher incidence in that older subgroup.[2] In a separate 52-week RCT context, semaglutide produced 8.8% weight loss alongside significantly lower total hip and lumbar spine BMD and elevated bone resorption markers compared to placebo.[2]
The Weill Cornell cohort study is observational and retrospective, drawn from a single center's patient population already selected for elevated fracture risk — the findings may not generalize to a general, lower-risk GLP-1 user population.
The age 75+ fracture signal comes from a subgroup analysis within a much larger cardiovascular outcomes trial not specifically designed to study bone health as a primary endpoint — subgroup findings from CVOTs warrant replication in bone-focused trial designs before being treated as definitive.
Regulatory context
In December 2025, the FDA qualified total hip BMD as a surrogate endpoint for osteoporosis drug development through the FNIH SABRE Project — a regulatory development that, while not specific to GLP-1s, signals the mechanism by which future GLP-1 trials could formally incorporate bone health as a monitored or even primary outcome rather than an incidental safety finding.[3]
Compare GLP-1 telehealth providers
Source GLP-1 tracks pricing, licensing, and provider structure across the market.